Canaccord Genuity Group Has Lowered Expectations for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price

Posted by Stanley Muller on Nov 4th, 2026

Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Free Report) had its price objective reduced by Canaccord Genuity Group from $39.00 to $34.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Canaccord Genuity Group‘s target price would indicate a potential upside of 98.14% from the stock’s current price.

A number of other equities research analysts have also commented on the company. UBS Group assumed coverage on Ultragenyx Pharmaceutical in a research report on Thursday, October 15th. They set a “neutral” rating and a $16.00 price target on the stock. Cantor Fitzgerald increased their target price on Ultragenyx Pharmaceutical from $33.00 to $39.00 and gave the stock an “overweight” rating in a research note on Friday, September 18th. Wall Street Zen raised Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Wedbush dropped their target price on shares of Ultragenyx Pharmaceutical from $25.00 to $22.00 and set a “neutral” rating on the stock in a report on Wednesday. Finally, Royal Bank Of Canada lowered shares of Ultragenyx Pharmaceutical from a “moderate buy” rating to a “hold” rating in a research note on Thursday, September 3rd. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Ultragenyx Pharmaceutical currently has an average rating of “Hold” and an average price target of $33.45.

Read Our Latest Research Report on RARE

Ultragenyx Pharmaceutical Price Performance

Shares of NASDAQ RARE traded up $0.53 during midday trading on Wednesday, reaching $17.16. 7,509,139 shares of the stock were exchanged, compared to its average volume of 2,873,975. The business has a 50-day simple moving average of $16.64 and a two-hundred day simple moving average of $22.81. The company has a market capitalization of $1.69 billion, a price-to-earnings ratio of -2.94 and a beta of 0.37. Ultragenyx Pharmaceutical has a 12 month low of $12.73 and a 12 month high of $39.89.

Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Free Report) last released its quarterly earnings data on Tuesday, November 3rd. The biopharmaceutical company reported ($1.16) EPS for the quarter, missing analysts’ consensus estimates of ($1.10) by ($0.06). The company had revenue of $173.00 million for the quarter, compared to analyst estimates of $182.49 million. The firm’s quarterly revenue was up 8.2% compared to the same quarter last year. During the same period in the prior year, the company posted ($1.81) EPS. Equities research analysts expect that Ultragenyx Pharmaceutical will post -4.30 earnings per share for the current fiscal year.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other news, CFO Howard Horn sold 7,066 shares of the company’s stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $15.27, for a total transaction of $107,897.82. Following the completion of the transaction, the chief financial officer directly owned 89,229 shares of the company’s stock, valued at $1,362,526.83. This represents a 7.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 8,510 shares of company stock worth $127,561 over the last ninety days. 5.20% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

A number of large investors have recently bought and sold shares of RARE. BlackRock Inc. acquired a new stake in shares of Ultragenyx Pharmaceutical in the second quarter valued at approximately $355,746,000. Bank of America Corp DE bought a new stake in shares of Ultragenyx Pharmaceutical in the second quarter worth $38,347,000. Candriam S.C.A. boosted its holdings in Ultragenyx Pharmaceutical by 37.1% during the first quarter. Candriam S.C.A. now owns 1,096,182 shares of the biopharmaceutical company’s stock worth $22,965,000 after purchasing an additional 296,798 shares during the last quarter. Jefferies Financial Group Inc. acquired a new position in Ultragenyx Pharmaceutical during the second quarter worth $31,040,000. Finally, Eagle Health Investments LP acquired a new position in Ultragenyx Pharmaceutical during the first quarter worth $18,522,000. Institutional investors and hedge funds own 97.67% of the company’s stock.

Key Stories Impacting Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

Positive Sentiment: Ultragenyx reported FDA approvals for GENGLYCOS and FAYUVI and agreed to sell two priority review vouchers for a combined $413 million. The proceeds could provide a meaningful financial boost. Ultragenyx Q3 results and company announcement
Positive Sentiment: The company reaffirmed its 2027 profitability outlook and said expense reductions are expected to lower 2027 R&D spending by at least 50% compared with 2025. Ultragenyx Q3 results and company announcement
Positive Sentiment: TD Cowen raised its price target to $19 and maintained a Buy rating. TD Cowen recommendations
Neutral Sentiment: Analyst views were mixed: Morgan Stanley, Wells Fargo and Wedbush raised their targets, while retaining Equal Weight or Neutral ratings; Goldman Sachs cut its target to $17 and kept a Neutral rating. Morgan Stanley recommendations Wells Fargo recommendations Wedbush recommendations Goldman Sachs recommendations
Negative Sentiment: Q3 revenue of $173 million was below the roughly $182 million consensus, and the $1.16-per-share loss was wider than expected. Revenue still grew 8.2% year over year, and the loss narrowed from $1.81 a year earlier. Ultragenyx Q3 earnings
Negative Sentiment: A Seeking Alpha analysis argued that growth remains reliant on CRYSVITA, newer launches contribute little, and the pivot toward profitability depends heavily on deep R&D cuts amid pipeline setbacks. Ultragenyx analysis

About Ultragenyx Pharmaceutical

(Get Free Report)

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare diseases. The company concentrates on conditions with significant unmet medical needs, including genetic, metabolic and endocrine disorders, and uses biologics, small molecules and gene therapy approaches in its research and development programs.

Ultragenyx’s commercial portfolio includes Crysvita (burosumab), a treatment for X-linked hypophosphatemia and related disorders; Mepsevii (vestronidase alfa), an enzyme replacement therapy for mucopolysaccharidosis VII; and Dojolvi (triheptanoin), a therapy for long-chain fatty acid oxidation disorders.